Companies Dominating the CDK4/6 Inhibitor Drugs Landscape
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis AG
- Eli Lilly and Company
- Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- AstraZeneca plc
- Celltrion, Inc
- Merck & Co., Inc.
- Halozyme Inc.
- Sanofi
- NATCO Pharma Limited
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of CDK4/6 inhibitor drugs is estimated at USD 15.82 billion.
The CDK4/6 inhibitor drugs market size was over USD 12.31 billion in 2024 and is poised to exceed USD 91.66 billion by 2037, growing at over 16.7% CAGR during the forecast period i.e., between 2025-2037. The growing cases of breast cancer and increasing advancement in drug development will propel the market growth.
North America industry is poised to account for largest revenue share of 69% by 2037, impelled by increasing number of clinical trials in the region.
The major players in the market are Pfizer Inc., Novartis AG, Eli Lilly and Company, Jiangsu Hengrui Pharmaceuticals Co., Ltd., AstraZeneca plc, Celltrion, Inc, Merck & Co., Inc., Halozyme Inc., Sanofi, NATCO Pharma Limited
